Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Free Cash Flow: 2019-2025

Historic Free Cash Flow for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to $108.7 million.

  • Harmony Biosciences Holdings' Free Cash Flow rose 54.14% to $108.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $296.9 million, marking a year-over-year increase of 34.84%. This contributed to the annual value of $218.7 million for FY2024, which is 0.19% down from last year.
  • As of Q3 2025, Harmony Biosciences Holdings' Free Cash Flow stood at $108.7 million, which was up 36.99% from $79.3 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Free Cash Flow peaked at $108.7 million during Q3 2025, and registered a low of $12.5 million during Q1 2021.
  • Its 3-year average for Free Cash Flow is $60.0 million, with a median of $63.1 million in 2023.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' Free Cash Flow spiked by 273.57% in 2021, and later decreased by 28.92% in 2022.
  • Over the past 5 years, Harmony Biosciences Holdings' Free Cash Flow (Quarterly) stood at $37.5 million in 2021, then dropped by 28.92% to $26.7 million in 2022, then surged by 186.97% to $76.6 million in 2023, then fell by 1.97% to $75.0 million in 2024, then surged by 54.14% to $108.7 million in 2025.
  • Its last three reported values are $108.7 million in Q3 2025, $79.3 million for Q2 2025, and $33.9 million during Q1 2025.